Literature DB >> 27341462

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization.

Yogin Patel1, Ji S Lee2, Hexin Chen3.   

Abstract

In this article, we describe a detailed protocol for miRNA detection in breast cancer tissue using in situ hybridization with a digoxigenin-labelled LNA (Locked Nucleic Acid) probe. The probe was recognized by anti-DIG alkaline phosphatase antibodies and later developed using alkaline phosphatase substrate producing fluorescence signals. Here we utilized miRNA in situ hybridization (MISH) technique to analyze expression of miR-489 in tissues from breast cancer patients. This technique can detect the localization of miRNA of interest in individual tissue samples. This technique can be used to compare the expression of desired miRNA in tumor tissue with that in adjacent normal tissue and to identify the specific structures responsible for expressing this miRNA. This technique can be very useful in answering certain clinical questions, such as role of specific miRNA in the development of cancer. Our results indicate that mammary epithelial cells express significantly higher levels of miR-489 than adjacent tumor cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27341462      PMCID: PMC4922489          DOI: 10.3791/53928

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  15 in total

Review 1.  In situ detection of microRNAs in paraffin embedded, formalin fixed tissues and the co-localization of their putative targets.

Authors:  Gerard J Nuovo
Journal:  Methods       Date:  2010-08-17       Impact factor: 3.608

2.  miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer.

Authors:  Hailin Tang; Peng Liu; Lu Yang; Xinhua Xie; Feng Ye; Minqing Wu; Xiaoping Liu; Bo Chen; Lijuan Zhang; Xiaoming Xie
Journal:  Mol Cancer Ther       Date:  2014-10-15       Impact factor: 6.261

3.  microRNA-146 up-regulation predicts the prognosis of non-small cell lung cancer by miRNA in situ hybridization.

Authors:  Jiangchao Li; Hong Yang; Yan Li; Ying Liu; Shupeng Chen; Cuiling Qi; Qianqian Zhang; Tian Lan; Xiaodong He; Xin-Yuan Guan; Lijing Wang
Journal:  Exp Mol Pathol       Date:  2014-01-18       Impact factor: 3.362

4.  MicroRNA-224 upregulation and AKT activation synergistically predict poor prognosis in patients with hepatocellular carcinoma.

Authors:  Lingxiang Yu; Jiabin Zhang; Xiaodong Guo; Zhiwei Li; Peirui Zhang
Journal:  Cancer Epidemiol       Date:  2014-06-10       Impact factor: 2.984

5.  Paraffin embedding tissue samples for sectioning.

Authors:  Andrew H Fischer; Kenneth A Jacobson; Jack Rose; Rolf Zeller
Journal:  CSH Protoc       Date:  2008-05-01

6.  MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.

Authors:  C Oneyama; J Ikeda; D Okuzaki; K Suzuki; T Kanou; Y Shintani; E Morii; M Okumura; K Aozasa; M Okada
Journal:  Oncogene       Date:  2011-03-07       Impact factor: 9.867

Review 7.  MicroRNAs in pathogenesis of breast cancer: Implications in diagnosis and treatment.

Authors:  Nirav R Shah; Hexin Chen
Journal:  World J Clin Oncol       Date:  2014-05-10

8.  The influence of locked nucleic acid residues on the thermodynamic properties of 2'-O-methyl RNA/RNA heteroduplexes.

Authors:  Elzbieta Kierzek; Anna Ciesielska; Karol Pasternak; David H Mathews; Douglas H Turner; Ryszard Kierzek
Journal:  Nucleic Acids Res       Date:  2005-09-09       Impact factor: 16.971

9.  Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue.

Authors:  John Le Quesne; Julia Jones; Joanna Warren; Sarah-Jane Dawson; H Raza Ali; Helen Bardwell; Fiona Blows; Paul Pharoah; Carlos Caldas
Journal:  J Pathol       Date:  2012-05-08       Impact factor: 7.996

10.  Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.

Authors:  Xing-Ming Ye; Hua-Yu Zhu; Wen-Dong Bai; Ting Wang; Lei Wang; Ying Chen; An-Gang Yang; Lin-Tao Jia
Journal:  BMC Cancer       Date:  2014-02-26       Impact factor: 4.430

View more
  1 in total

1.  Autophagy, Cell Viability, and Chemoresistance Are Regulated By miR-489 in Breast Cancer.

Authors:  Mithil Soni; Yogin Patel; Eleni Markoutsa; Chunfa Jie; Shou Liu; Peisheng Xu; Hexin Chen
Journal:  Mol Cancer Res       Date:  2018-05-21       Impact factor: 5.852

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.